MCID: SBP001
MIFTS: 50

Subependymal Giant Cell Astrocytoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Subependymal Giant Cell Astrocytoma

MalaCards integrated aliases for Subependymal Giant Cell Astrocytoma:

Name: Subependymal Giant Cell Astrocytoma 12 49 55 36 14 69
Sega 12 49 55
Astrocytoma Subependymal Giant Cell 51

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5077
MeSH 41 D001254
NCIt 46 C3696
SNOMED-CT 64 1586004 449799008
Orphanet 55 ORPHA251618
UMLS via Orphanet 70 C0205768
ICD10 via Orphanet 33 D43.2
KEGG 36 H01692
UMLS 69 C0205768

Summaries for Subependymal Giant Cell Astrocytoma

MalaCards based summary : Subependymal Giant Cell Astrocytoma, also known as sega, is related to tuberous sclerosis 1 and gemistocytic astrocytoma, and has symptoms including seizures and headache. An important gene associated with Subependymal Giant Cell Astrocytoma is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are mTOR signaling pathway and Angiopoietin Like Protein 8 Regulatory Pathway. The drugs Afinitor and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and endothelial, and related phenotype is behavior/neurological.

Wikipedia : 72 Subependymal giant cell astrocytoma (SEGA, SGCA, or SGCT) is a low-grade astrocytic brain tumor... more...

Related Diseases for Subependymal Giant Cell Astrocytoma

Diseases related to Subependymal Giant Cell Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 tuberous sclerosis 1 31.6 TSC1 TSC2
2 gemistocytic astrocytoma 30.5 GFAP S100B
3 angiomyolipoma 30.4 MTOR TSC1 TSC2
4 obstructive hydrocephalus 30.3 GFAP SYP
5 astrocytoma 30.1 GFAP NES S100B SYP TSC2
6 giant cell glioblastoma 30.0 GFAP SYP
7 tuberous sclerosis 29.7 GFAP MTOR S100B SYP TSC1 TSC2
8 hydrocephalus 29.3 ENO2 GFAP NES SYP
9 central neurocytoma 29.1 ENO2 GFAP NES SYP
10 dysembryoplastic neuroepithelial tumor 28.9 GFAP NES S100B SYP
11 subependymoma 28.6 ENO2 GFAP NES SYP TSC2
12 primitive neuroectodermal tumor of the cervix uteri 10.5 ENO2 GFAP
13 melanotic medulloblastoma 10.5 ENO2 GFAP
14 cerebellar medulloblastoma 10.4 ENO2 GFAP
15 plexiform schwannoma 10.4 ENO2 GFAP
16 microcystic meningioma 10.4 ENO2 GFAP
17 integumentary system benign neoplasm 10.4 ENO2 GFAP
18 hemimegalencephaly 10.4 GFAP MTOR
19 dysgerminoma of ovary 10.3 ENO2 GFAP
20 syringocystadenoma papilliferum 10.3 GFAP S100B
21 bednar tumor 10.3 ENO2 S100B
22 chordoid glioma 10.3 GFAP S100B
23 myxopapillary ependymoma 10.3 GFAP S100B
24 juvenile pilocytic astrocytoma 10.3 ENO2 GFAP
25 epithelioid malignant peripheral nerve sheath tumor 10.3 ENO2 S100B
26 middle cerebral artery infarction 10.3 ENO2 S100B
27 ossifying fibromyxoid tumor 10.3 ENO2 S100B
28 syringoma 10.3 GFAP S100B
29 adult hepatocellular carcinoma 10.3 TSC1 TSC2
30 head injury 10.3 ENO2 S100B
31 perineurioma 10.3 GFAP S100B
32 desmoplastic infantile ganglioglioma 10.3 GFAP SYP
33 multilocular clear cell renal cell carcinoma 10.3 TSC1 TSC2
34 extraventricular neurocytoma 10.3 GFAP SYP
35 lung combined type small cell carcinoma 10.3 GFAP SYP
36 cellular ependymoma 10.3 GFAP SYP
37 gangliocytoma 10.3 GFAP SYP
38 rhabdoid meningioma 10.3 GFAP SYP
39 pilomyxoid astrocytoma 10.3 GFAP SYP
40 malignant sertoli cell tumor 10.3 ENO2 SYP
41 urinary bladder small cell neuroendocrine carcinoma 10.3 ENO2 SYP
42 lissencephaly with cerebellar hypoplasia 10.2 TSC1 TSC2
43 sinonasal undifferentiated carcinoma 10.2 ENO2 SYP
44 auditory system cancer 10.2 ENO2 SYP
45 meningeal melanocytoma 10.2 ENO2 S100B
46 chiari malformation 10.2 GFAP SYP
47 cutaneous ganglioneuroma 10.2 ENO2 SYP
48 sensory organ benign neoplasm 10.2 ENO2 SYP
49 middle ear adenoma 10.2 ENO2 SYP
50 gallbladder small cell carcinoma 10.2 ENO2 SYP

Graphical network of the top 20 diseases related to Subependymal Giant Cell Astrocytoma:



Diseases related to Subependymal Giant Cell Astrocytoma

Symptoms & Phenotypes for Subependymal Giant Cell Astrocytoma

UMLS symptoms related to Subependymal Giant Cell Astrocytoma:


seizures, headache

MGI Mouse Phenotypes related to Subependymal Giant Cell Astrocytoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.17 ENO2 GFAP MTOR S100B SYP TSC1

Drugs & Therapeutics for Subependymal Giant Cell Astrocytoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 45 EVEROLIMUS Novartis March 2009

Drugs for Subependymal Giant Cell Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
4 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
6 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Cisplatin Approved Phase 3,Phase 1 15663-27-1 2767 441203 84093
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
12
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
16 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
17 Dermatologic Agents Phase 3,Phase 1
18 Adjuvants, Anesthesia Phase 3
19 Analgesics Phase 3,Phase 1
20 Analgesics, Opioid Phase 3
21 Anesthetics Phase 3
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Central Nervous System Depressants Phase 3
25 Liver Extracts Phase 3,Phase 1,Phase 2
26 Narcotics Phase 3
27 Peripheral Nervous System Agents Phase 3,Phase 1
28 Antiemetics Phase 3,Phase 1
29 Autonomic Agents Phase 3,Phase 1
30 BB 1101 Phase 3,Phase 2,Phase 1
31 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
32 Emetics Phase 3
33 Gastrointestinal Agents Phase 3,Phase 1
34 Neurotransmitter Agents Phase 3,Early Phase 1
35 Anti-Allergic Agents Phase 3
36 Antipruritics Phase 3
37 Histamine Antagonists Phase 3
38 Histamine H1 Antagonists Phase 3
39
Histamine Phosphate Phase 3 51-74-1 65513
40
Serotonin Phase 3 50-67-9 5202
41 Serotonin Agents Phase 3
42 Serotonin Antagonists Phase 3
43 Cola Nutraceutical Phase 3
44
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
45
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
46
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
47
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
48
Armodafinil Approved, Investigational Phase 2 112111-43-0
49
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
50
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142

Interventional clinical trials:

(show top 50) (show all 56)

# Name Status NCT ID Phase Drugs
1 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4 Everolimus;Envirolimus drug class as prescribed by Physician
2 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3 Everolimus;Placebo
3 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
7 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
8 Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex Completed NCT00411619 Phase 1, Phase 2 Everolimus
9 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
10 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
11 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
12 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
13 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
14 A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Recruiting NCT02451696 Phase 2 Everolimus
15 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
16 Bevacizumab in Recurrent Grade II and III Glioma Active, not recruiting NCT01164189 Phase 2 Temozolomide
17 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2 everolimus;temozolomide
18 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
19 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
20 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
21 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
22 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
23 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
24 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
25 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
26 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
27 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
28 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
29 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
30 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
31 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
32 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
33 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
34 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
35 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
36 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
37 Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
38 Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
39 Anakinra or Denosumab and Everolimus in Advanced Cancer Recruiting NCT01624766 Phase 1 Everolimus;Anakinra;Denosumab
40 Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer Active, not recruiting NCT01087554 Phase 1 Sirolimus;Vorinostat;Everolimus;Temsirolimus
41 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Active, not recruiting NCT02186509 Phase 1 Alisertib
42 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
43 Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors Terminated NCT00112619 Phase 1 topotecan hydrochloride
44 Study of Blood and Cheek Cell Samples From Patients With Glioma Completed NCT01009307
45 Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma Completed NCT00999622
46 Study of Tissue Samples From Patients With Glioma or Other Brain Tumors Completed NCT00967200
47 Metabolic Syndrome in Childhood Cancer Survivors Completed NCT00920738
48 Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors Completed NCT00499798
49 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 imatinib mesylate
50 Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain Completed NCT00452868 Early Phase 1 Donepezil

Search NIH Clinical Center for Subependymal Giant Cell Astrocytoma

Genetic Tests for Subependymal Giant Cell Astrocytoma

Anatomical Context for Subependymal Giant Cell Astrocytoma

MalaCards organs/tissues related to Subependymal Giant Cell Astrocytoma:

38
Brain, Spinal Cord, Endothelial, Breast, Liver, T Cells, Bone

Publications for Subependymal Giant Cell Astrocytoma

Articles related to Subependymal Giant Cell Astrocytoma:

(show top 50) (show all 152)
# Title Authors Year
1
Efficacy and safety of everolimus in patients younger than 12a8^months with congenital subependymal giant cell astrocytoma. ( 29395661 )
2018
2
The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. ( 28993887 )
2018
3
Trapped ventricle after laser ablation of a subependymal giant cell astrocytoma complicated by intraventricular gadolinium extravasation: case report. ( 29451453 )
2018
4
Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation. ( 28074282 )
2017
5
Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report. ( 28516078 )
2017
6
Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus. ( 28511812 )
2017
7
Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas. ( 28162859 )
2017
8
Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex. ( 28866062 )
2017
9
Subependymal Giant Cell Astrocytoma: Associated Hyperproteinorrhachia Causing Shunt Failures and Nonobstructive Hydrocephalus - Report of Successful Treatment with Long-term Follow-up. ( 29114301 )
2017
10
Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature. ( 26861567 )
2016
11
Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). ( 27860334 )
2016
12
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. ( 27013816 )
2016
13
Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis. ( 26942030 )
2016
14
Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase. ( 27390104 )
2016
15
Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex. ( 26929034 )
2016
16
Thyroid transcription factor-1 distinguishes subependymal giant cell astrocytoma from its mimics and supports its cell origin from the progenitor cells in the medial ganglionic eminence. ( 27910945 )
2016
17
Variability of Dose and Level of Sirolimus in a Patient With Tuberous Sclerosis Complex and Subependymal Giant Cell Astrocytoma. ( 27082208 )
2016
18
EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. ( 27502586 )
2016
19
Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report. ( 27690646 )
2016
20
Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases. ( 27625244 )
2016
21
Subependymal giant cell astrocytoma in a genetically negative tuberous sclerosis complex adult: Case report. ( 27690251 )
2016
22
Retraction Note to: Subependymal giant cell astrocytoma: current concepts, management, and future directions. ( 26922080 )
2016
23
Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). ( 25929843 )
2015
24
Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report. ( 25978531 )
2015
25
The clinical characteristics of subependymal giant cell astrocytoma: five cases. ( 25977907 )
2015
26
Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. ( 26381530 )
2015
27
Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. ( 26706014 )
2015
28
Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study. ( 25525770 )
2015
29
BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. ( 25346165 )
2015
30
Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma. ( 25909870 )
2015
31
Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. ( 26173783 )
2015
32
Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex. ( 26552385 )
2015
33
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. ( 25456370 )
2014
34
Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. ( 25227171 )
2014
35
A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. ( 24180681 )
2014
36
The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. ( 24729041 )
2014
37
An unusually aggressive clinical behavior in a case of atypical subependymal giant cell astrocytoma. ( 25387628 )
2014
38
Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. ( 24507694 )
2014
39
Subependymal giant cell astrocytoma: current concepts, management, and future directions. ( 24549759 )
2014
40
Thyroid transcription factor-1 and epithelial membrane antigen expression in four cases of subependymal giant cell astrocytoma. ( 25195621 )
2014
41
Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex. ( 25143481 )
2014
42
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. ( 23158522 )
2013
43
Congenital Segmental Lymphedema in Tuberous Sclerosis Complex With Associated Subependymal Giant Cell Astrocytomas Treated with Mammalian Target of Rapamycin Inhibitors. ( 24056156 )
2013
44
Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. ( 23325902 )
2013
45
Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. ( 23391693 )
2013
46
Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. ( 22805244 )
2013
47
Subependymal giant cell astrocytoma with intratumoral hemorrhage. ( 23414132 )
2013
48
The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. ( 23183057 )
2013
49
Subependymal Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex:: Considerations for Surgical or Pharmacotherapeutic Intervention. ( 24105488 )
2013
50
Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. ( 24138953 )
2013

Variations for Subependymal Giant Cell Astrocytoma

Expression for Subependymal Giant Cell Astrocytoma

Search GEO for disease gene expression data for Subependymal Giant Cell Astrocytoma.

Pathways for Subependymal Giant Cell Astrocytoma

Pathways related to Subependymal Giant Cell Astrocytoma according to KEGG:

36
# Name Kegg Source Accession
1 mTOR signaling pathway hsa04150

Pathways related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 MTOR TSC1 TSC2
2
Show member pathways
12.26 MTOR TSC1 TSC2
3 12.24 ENO2 GFAP S100B SYP
4
Show member pathways
12.21 MTOR TSC1 TSC2
5
Show member pathways
12.19 MTOR TSC1 TSC2
6
Show member pathways
12.17 MTOR TSC1 TSC2
7
Show member pathways
12.16 MTOR TSC1 TSC2
8
Show member pathways
12.06 MTOR TSC1 TSC2
9 12.02 MTOR TSC1 TSC2
10
Show member pathways
11.99 MTOR TSC1 TSC2
11
Show member pathways
11.97 MTOR TSC1 TSC2
12 11.93 MTOR TSC1 TSC2
13 11.89 MTOR TSC1 TSC2
14
Show member pathways
11.87 MTOR TSC1 TSC2
15
Show member pathways
11.85 MTOR TSC1 TSC2
16 11.77 MTOR TSC1 TSC2
17 11.74 MTOR TSC1 TSC2
18 11.65 MTOR TSC1 TSC2
19 11.47 MTOR TSC1 TSC2
20 11.31 TSC1 TSC2
21 11.3 MTOR TSC2
22 11.28 MTOR TSC1 TSC2
23 11.16 MTOR TSC1 TSC2
24 11.07 MTOR TSC2
25 11.02 MTOR TSC2
26 10.96 MTOR TSC1 TSC2
27 10.82 GFAP NES S100B SYP
28 10.79 MTOR TSC1
29 10.66 MTOR TSC1 TSC2

GO Terms for Subependymal Giant Cell Astrocytoma

Cellular components related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 TSC1-TSC2 complex GO:0033596 8.62 TSC1 TSC2

Biological processes related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of stress fiber assembly GO:0051496 9.51 MTOR TSC1
2 cell cycle arrest GO:0007050 9.5 MTOR TSC1 TSC2
3 regulation of protein kinase activity GO:0045859 9.49 MTOR TSC1
4 long-term synaptic potentiation GO:0060291 9.48 GFAP S100B
5 negative regulation of TOR signaling GO:0032007 9.46 TSC1 TSC2
6 negative regulation of insulin receptor signaling pathway GO:0046627 9.43 TSC1 TSC2
7 positive regulation of macroautophagy GO:0016239 9.4 TSC1 TSC2
8 regulation of neuronal synaptic plasticity GO:0048168 9.37 S100B SYP
9 negative regulation of macroautophagy GO:0016242 9.26 MTOR TSC1
10 positive regulation of glial cell proliferation GO:0060252 9.16 GFAP MTOR
11 anoikis GO:0043276 8.96 MTOR TSC2
12 negative regulation of cell size GO:0045792 8.62 MTOR TSC1

Sources for Subependymal Giant Cell Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....